EMA Recommends Granting a Marketing Authorisation for Accordpharma Enzalutamide By Ogkologos - December 5, 2025 295 0 Facebook Twitter Google+ Pinterest WhatsApp It is a generic and hybrid of Xtandi, which has been authorised in the EU since 2013 Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR FDA Grants Accelerated Approval to Lurbinectedin for Metastatic SCLC June 19, 2020 Enhertu May Be Preferred Therapy for Some Metastatic Breast Cancers October 19, 2021 A Combination of Trifluridine-Tipiracil Plus Bevacizumab Results in Longer Overall Survival... May 9, 2023 Altering Chemotherapy Improves Outcomes in Early-Stage Pancreatic Cancer June 28, 2018 Load more HOT NEWS FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell... Sun Exposure Lowers Risk of Breast Cancer, Study Finds Excellence in cancer research nursing: Celebrating innovation during tough times EMA Recommends Granting a Conditional Marketing Authorisation for Zanidatamab
